Short-acting β2-agonist prescription patterns in patients with asthma in Turkey: results from SABINA III

Simple item page
dc.contributor.authorYorgancıoğlu A.
dc.contributor.authorAksu K.
dc.contributor.authorNaycı S.A.
dc.contributor.authorEdiger D.
dc.contributor.authorMungan D.
dc.contributor.authorGül U.
dc.contributor.authorBeekman M.J.H.I.
dc.contributor.authorKızılırmak D.
dc.contributor.authorAltıntaş N.
dc.contributor.authorBulut İ.
dc.contributor.authorÇağatay T.
dc.contributor.authorGemicioğlu B.
dc.contributor.authorİnce Ö.
dc.contributor.authorOğuzülgen K.
dc.contributor.authorKalpaklıoğlu F.
dc.contributor.authorBaççıoğlu A.
dc.contributor.authorAksu F.
dc.contributor.authorAltuntaş M.
dc.contributor.authorErkekol F.Ö.
dc.contributor.authorKarakaya G.
dc.contributor.authorKalyoncu A.F.
dc.contributor.authorDamadoğlu E.
dc.contributor.authorHanta İ.
dc.contributor.authorAltunok E.
dc.contributor.authorÖzer A.
dc.contributor.authorYuluğ D.P.
dc.contributor.authorGülbaş G.
dc.contributor.authorSüerdem M.
dc.contributor.authorYormaz B.
dc.contributor.authorCeylan E.
dc.contributor.authorErge D.
dc.contributor.authorÇilli A.
dc.contributor.authorDoğan B.C.
dc.contributor.authorErel F.
dc.contributor.authorSevinç C.
dc.contributor.authorAnar C.
dc.contributor.authorPekbak G.
dc.contributor.authorErbay M.
dc.date.accessioned2024-07-22T08:03:51Z
dc.date.available2024-07-22T08:03:51Z
dc.date.issued2022
dc.description.abstractBackground: Over-reliance on short-acting β2-agonists (SABAs) is associated with poor asthma outcomes. However, the extent of SABA use in Turkey is unclear owing to a lack of comprehensive healthcare databases. Here, we describe the demographics, disease characteristics and treatment patterns from the Turkish cohort of the SABA use IN Asthma (SABINA) III study. Methods: This observational, cross-sectional study included patients aged ≥ 12 years with asthma from 24 centres across Turkey. Data on sociodemographics, disease characteristics and asthma treatments were collected using electronic case report forms. Patients were classified by investigator-defined asthma severity (guided by the 2017 Global Initiative for Asthma [GINA]) and practice type (primary/specialist care). The primary objective was to describe SABA prescription patterns in the 12 months prior to the study visit. Results: Overall, 579 patients were included (mean age [standard deviation; SD]: 47.4 [16.1] years; 74.3% female), all of whom were treated by specialists. Most patients had moderate-to-severe asthma (82.7%, GINA steps 3–5), were overweight or obese (70.5%), had high school or university/post-graduate education (51.8%) and reported fully reimbursed healthcare (97.1%). The mean (SD) asthma duration was 12.0 (9.9) years. Asthma was partly controlled/uncontrolled in 56.3% of patients, and 46.5% experienced ≥ 1 severe exacerbation in the preceding 12 months. Overall, 23.9% of patients were prescribed ≥ 3 SABA canisters in the previous 12 months (considered over-prescription); 42.9% received no SABA prescriptions. As few patients had mild asthma, only 5.7% were prescribed SABA monotherapy. Therefore, most patients (61.5%) were prescribed SABA in addition to maintenance therapy, with 42.8% receiving ≥ 3 SABA canisters in the previous 12 months. Inhaled corticosteroids (ICS), ICS + a long-acting β-agonist fixed-dose combination and oral corticosteroids were prescribed to 14.5%, 88.3% and 28.5% of all patients, respectively. Additionally, 10.2% of patients purchased SABA over the counter, of whom 27.1% purchased ≥ 3 canisters in the preceding 12 months. Conclusions: Despite all patients being treated by specialists and most receiving fully reimbursed healthcare, nearly a quarter of patients received prescriptions for ≥ 3 SABA canisters in the previous 12 months. This highlights a public health concern and emphasizes the need to align clinical practices with the latest evidence-based recommendations. © 2022, The Author(s).
dc.identifier.DOI-ID10.1186/s12890-022-02008-9
dc.identifier.issn14712466
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12469
dc.language.isoEnglish
dc.publisherBioMed Central Ltd
dc.rightsAll Open Access; Gold Open Access; Green Open Access
dc.subjectAdolescent
dc.subjectAdrenal Cortex Hormones
dc.subjectAsthma
dc.subjectCross-Sectional Studies
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectPrescriptions
dc.subjectTurkey
dc.subjectbeta 2 adrenergic receptor stimulating agent
dc.subjectcorticosteroid
dc.subjectcorticosteroid
dc.subjectadult
dc.subjectArticle
dc.subjectasthma
dc.subjectcohort analysis
dc.subjectcross-sectional study
dc.subjectdemography
dc.subjectdisease duration
dc.subjectdisease exacerbation
dc.subjectdisease severity
dc.subjectevidence based medicine
dc.subjectfemale
dc.subjecthealth center
dc.subjecthuman
dc.subjectmaintenance therapy
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmedical specialist
dc.subjectmiddle aged
dc.subjectobesity
dc.subjectobservational study
dc.subjectpersonal experience
dc.subjectpostgraduate education
dc.subjectprescription
dc.subjectsocial status
dc.subjectTurkey (republic)
dc.subjectadolescent
dc.subjectcomplication
dc.subjectturkey (bird)
dc.titleShort-acting β2-agonist prescription patterns in patients with asthma in Turkey: results from SABINA III
dc.typeArticle

Files

Collections

Scopus Koleksiyonu